



Printing date 10/14/2020 Revision date 10/14/2020

### 1 Identification

· Product identifier

· Trade name: Inhibitor Screening Human Plasma PAF-AH

· Synonym Human Plasma PAF-AH

· Article number: 10004803, 007818

· Application of the substance / the mixture For research use only, not for human or veterinary use.

· Details of the supplier of the safety data sheet

Manufacturer/Supplier: Cayman Chemical Co. 1180 E. Ellsworth Rd. Ann Arbor, MI 48108

USA

· Information department: Product safety department

· Emergency telephone number:

During normal opening times: +1 (734) 971-3335

US/CANADA: 800-424-9300

Outside US/CANADA: 703-741-5970

### 2 Hazard(s) identification

· Classification of the substance or mixture

The product is not classified, according to the Globally Harmonized System (GHS).

- · Label elements
- · GHS label elements None
- · Hazard pictograms None
- · Signal word None
- · Hazard statements None
- · Classification system:
- NFPA ratings (scale 0 4)



Health = 0Fire = 0Reactivity = 0

· HMIS-ratings (scale 0 - 4)



Health = 0 Fire = 0

- Other hazards
- · Results of PBT and vPvB assessment
- · **PBT:** Not applicable.
- · vPvB: Not applicable.

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

(Contd. from page 1)

### 3 Composition/information on ingredients

· Chemical characterization: Mixtures

· **Description:** Mixture of the substances listed below with nonhazardous additions.

· Dangerous components: None

· Other ingredients		
CAS: 7732-18-5 RTECS: ZC0110000	Water	98.6295%
CAS: 7647-14-5 RTECS: VZ4725000	Sodium chloride	0.9%
CAS: 7778-77-0 RTECS: TC6615500	Potassium phosphate, Monobasic	0.27%
CAS: 9048-46-8 RTECS: MT6446000	Albumin, bovine	0.2%
	Human plasma PAF-AH intermediate	0.0005%

### 4 First-aid measures

- · Description of first aid measures
- · General information: No special measures required.
- After inhalation: Supply fresh air; consult doctor in case of complaints.
- · After skin contact: Generally the product does not irritate the skin.
- · After eye contact: Rinse opened eye for several minutes under running water.
- · After swallowing: If symptoms persist consult doctor.
- · Information for doctor:
- · Most important symptoms and effects, both acute and delayed

May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects. No further relevant information available.

Indication of any immediate medical attention and special treatment needed. No further relevant information available.

### 5 Fire-fighting measures

- · Extinguishing media
- Suitable extinguishing agents:

Use fire fighting measures that suit the environment.

A solid water stream may be inefficient.

- · Special hazards arising from the substance or mixture No further relevant information available.
- · Advice for firefighters
- · Protective equipment: No special measures required.

### **6 Accidental release measures**

- Personal precautions, protective equipment and emergency procedures Not required.
- · Environmental precautions: Dilute with plenty of water.
- · Methods and material for containment and cleaning up:

Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).

(Contd. on page 3)

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

(Contd. from page 2)

· Reference to other sections

See Section 7 for information on safe handling.

See Section 8 for information on personal protection equipment.

See Section 13 for disposal information.

Protective Action Criteria for Chemicals

1 Totoblive Action Official for Officialions	
PAC-1:	
7778-77-0 Potassium phosphate, Monobasic	9.6 mg/m³
· PAC-2:	
7778-77-0 Potassium phosphate, Monobasic	110 mg/m³
· PAC-3:	
7778-77-0 Potassium phosphate, Monobasic	630 mg/m³

## 7 Handling and storage

- · Handling:
- · Precautions for safe handling No special measures required.
- · Information about protection against explosions and fires: No special measures required.
- · Conditions for safe storage, including any incompatibilities

Keep container tightly closed.

Store in accordance with information listed on the product insert.

- · Storage:
- · Requirements to be met by storerooms and receptacles: No special requirements.
- · Information about storage in one common storage facility: Not required.
- Further information about storage conditions: None.
- · Specific end use(s) No further relevant information available.

### 8 Exposure controls/personal protection

- · Additional information about design of technical systems: No further data; see item 7.
- Control parameters
- · Components with limit values that require monitoring at the workplace:

The following constituent is the only constituent of the product which has a PEL, TLV or other recommended exposure limit.

The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit.

At this time, the remaining constituent has no known exposure limits.

At this time, the other constituents have no known exposure limits.

- · Additional information: The lists that were valid during the creation were used as basis.
- · Exposure controls
- · Personal protective equipment:
- General protective and hygienic measures:

The usual precautionary measures for handling chemicals should be followed.

- Breathing equipment: Not required.
- Protection of hands:

The glove material has to be impermeable and resistant to the product/ the substance/ the preparation. Due to missing tests no recommendation to the glove material can be given for the product/ the preparation/ the chemical mixture.

Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

(Contd. on page 4)

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

### Material of gloves

(Contd. from page 3)

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

Penetration time of glove material

The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

· Eye protection: Goggles recommended during refilling.

				4 =
9 Physica	1 200 0	hamica	INFOR	OPTION
7 F IIVSIL.0				
o i iiyolou		- I O I I I I O G		

<ul> <li>Information on basic physical and ch</li> <li>General Information</li> <li>Appearance:</li> </ul>	nemical properties
Form:	Liquid
Color:	According to product specification
· Odor:	Characteristic
· Structural Formula	H2 O
· Molecular Weight	18 g/mol
· Odor threshold:	Not determined.
· pH-value at 20 °C (68 °F):	7.4
<ul> <li>Change in condition</li> <li>Melting point/Melting range:</li> <li>Boiling point/Boiling range:</li> </ul>	0 °C (32 °F) Undetermined.
· Flash point:	Not applicable.
· Flammability (solid, gaseous):	Not applicable.
· Decomposition temperature:	Not determined.
· Auto igniting:	Product is not selfigniting.
· Danger of explosion:	Product does not present an explosion hazard.
· Explosion limits: Lower: Upper:	Not determined. Not determined.
· Vapor pressure at 20 °C (68 °F):	23 hPa (17.3 mm Hg)
<ul> <li>Density at 20 °C (68 °F):</li> <li>Relative density</li> <li>Vapor density</li> <li>Evaporation rate</li> </ul>	1 g/cm³ (8.345 lbs/gal) Not determined. Not determined. Not determined.
· Solubility in / Miscibility with Water:	Fully miscible.
· Partition coefficient (n-octanol/water	): Not determined.
· Viscosity:	
Dynamic:	Not determined.
Kinematic:	Not determined.

(Contd. on page 5)

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

(Contd. from page 4)

 Solvent content:
 98.6 %

 VOC content:
 0.00 %

 Solids content:
 0.0 %

 Other information
 No further relevant information available.

10 Stability and reactivity

- · Reactivity No further relevant information available.
- · Chemical stability
- · Thermal decomposition / conditions to be avoided:

No decomposition if used according to specifications.

- Possibility of hazardous reactions No dangerous reactions known.
- · Conditions to avoid No further relevant information available.
- · Incompatible materials: No further relevant information available.
- · Hazardous decomposition products: No dangerous decomposition products known.

## 11 Toxicological information

- · Information on toxicological effects
- · Acute toxicity:
- · Primary irritant effect:
- · on the skin: No irritant effect.
- · on the eye: No irritating effect.
- Sensitization: No sensitizing effects known.
- · Additional toxicological information:

The product is not subject to classification according to internally approved calculation methods for preparations:

When used and handled according to specifications, the product does not have any harmful effects according to our experience and the information provided to us.

- · Carcinogenic categories
- IARC (International Agency for Research on Cancer)

None of the ingredients is listed.

NTP (National Toxicology Program)

None of the ingredients is listed.

· OSHA-Ca (Occupational Safety & Health Administration)

None of the ingredients is listed.

### 12 Ecological information

- · Toxicity
- · Aquatic toxicity: No further relevant information available.
- Persistence and degradability No further relevant information available.
- · Behavior in environmental systems:
- · Bioaccumulative potential No further relevant information available.
- · **Mobility in soil** No further relevant information available.

(Contd. on page 6)

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

(Contd. from page 5)

- · Additional ecological information:
- · General notes: Not hazardous for water.
- · Results of PBT and vPvB assessment
- PBT: Not applicable.vPvB: Not applicable.
- · Other adverse effects No further relevant information available.

## 13 Disposal considerations

- · Waste treatment methods
- Recommendation: Smaller quantities can be disposed of with household waste.
- · Uncleaned packagings:
- · Recommendation: Disposal must be made according to official regulations.
- · Recommended cleansing agent: Water, if necessary with cleansing agents.

		<b>?</b>	
7/1	Char		
		forma	

· UN-Number			
· DOT, IMDG, IATA	not regulated		
DOT, IMIDO, IATA	not regulated		
· UN proper shipping name			
DOT, IMDG, IATA	not regulated		
DOT, IMIDO, IATA	not regulated		
· Transport hazard class(es)			
· DOT, ADN, IMDG, IATA			
· Class	not regulated		
Class	not regulated		
· Packing group			
· DOT, IMDG, IATA	not regulated		
DOT, IMIDO, IATA	not regulated		
· Environmental hazards:	Not applicable.		
· Special precautions for user	Not applicable.		
<u> </u>			
· Transport in bulk according to Annex II of			
MARPOL73/78 and the IBC Code	Not applicable.		
UN "Model Regulation":	not regulated		
<u> </u>	-		

## **15 Regulatory information**

- · Safety, health and environmental regulations/legislation specific for the substance or mixture
- · Sara
- Section 355 (extremely hazardous substances):

None of the ingredients is listed.

· Section 313 (Specific toxic chemical listings):

None of the ingredients is listed.

TSCA (Toxic Substances Control Act):

7732-18-5	Water	ACTIVE
7647-14-5	Sodium chloride	ACTIVE

(Contd. on page 7)

Printing date 10/14/2020 Revision date 10/14/2020

Trade name: Inhibitor Screening Human Plasma PAF-AH

7778-77-0 Potassium phosphate, Monobasic ACTIVE
9048-46-8 Albumin, bovine ACTIVE

· Hazardous Air Pollutants

None of the ingredients is listed.

Proposition 65

· Chemicals known to cause cancer:

None of the ingredients is listed.

· Chemicals known to cause reproductive toxicity for females:

None of the ingredients is listed.

· Chemicals known to cause reproductive toxicity for males:

None of the ingredients is listed.

· Chemicals known to cause developmental toxicity:

None of the ingredients is listed.

· Carcinogenic categories

· EPA (Environmental Protection Agency)

None of the ingredients is listed.

TLV (Threshold Limit Value established by ACGIH)

None of the ingredients is listed.

· NIOSH-Ca (National Institute for Occupational Safety and Health)

None of the ingredients is listed.

· Chemical safety assessment: A Chemical Safety Assessment has not been carried out.

### **16 Other information**

This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship.

- · Department issuing SDS: Environment protection department.
- · Contact: -
- · Date of preparation / last revision 10/14/2020 / -
- · Abbreviations and acronyms:

IMDG: International Maritime Code for Dangerous Goods

DOT: US Department of Transportation

IATA: International Air Transport Association

ACGIH: American Conference of Governmental Industrial Hygienists

EINECS: European Inventory of Existing Commercial Chemical Substances

ELINCS: European List of Notified Chemical Substances

CAS: Chemical Abstracts Service (division of the American Chemical Society)

NFPA: National Fire Protection Association (USA)

HMIS: Hazardous Materials Identification System (USA)

VOC: Volatile Organic Compounds (USA, ÉU)

PBT: Persistent, Bioaccumulative and Toxic

vPvB: very Persistent and very Bioaccumulative

NIOSH: National Institute for Occupational Safety

OSHA: Occupational Safety & Health

TLV: Threshold Limit Value

PEL: Permissible Exposure Limit

REL: Recommended Exposure Limit

\* Data compared to the previous version altered.